Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Minocycline controlled-release - OraPharma

Drug Profile

Minocycline controlled-release - OraPharma

Alternative Names: Arestin; Arestin LCM; Minocycline microspheres

Latest Information Update: 14 Sep 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Wyeth
  • Developer OraPharma; Wyeth
  • Class Amides; Anti-inflammatories; Antiacnes; Antibacterials; Dimethylamines; Neuroprotectants; Skin disorder therapies; Small molecules; Tetracyclines
  • Mechanism of Action Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Periodontitis
  • Discontinued Peri-implantitis

Most Recent Events

  • 09 Aug 2016 Discontinued - Phase-III for Peri-implantitis in United Kingdom, Sweden, Germany and USA (Subgingival) based on analysis of a phase III study data (Valeant Pharmaceuticals Form10-Q, August 2016)
  • 15 Mar 2016 Biomarkers information updated
  • 24 Jun 2014 OraPharma completes a phase III trial in Peri-implantitis in USA, United Kingdom, Germany & Sweden (NCT01539564)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top